Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Efficacy and Safety of Faster Aspart in Comparison to Insulin Aspart Among Indian Women with Gestational Diabetes

Author(s): Aneesh Ghosh*

Volume 19, Issue 8, 2023

Published on: 10 February, 2023

Article ID: e221222212124 Pages: 7

DOI: 10.2174/1573399819666221222154443

Price: $65

Abstract

Aims: The present study aimed to compare the pregnancy outcomes, efficacy, and safety of faster aspart with insulin aspart among Indian women with gestational diabetes.

Background: In several countries, fast-acting insulin aspart (faster aspart) has been approved for use in pregnancy. There is a lack of data related to maternal glycemic control and fetal and perinatal outcomes with faster aspart in gestational diabetes among the Indian population.

Objective: To compare and evaluate the efficacy and safety of faster aspart and insulin aspart in the management of gestational diabetes.

Methods: This retrospective study evaluated the medical records of 60 pregnant women diagnosed with gestational diabetes and managed with faster aspart or insulin aspart at a tertiary care center, between March 2019 and September 2020. Self-monitored blood glucose levels recorded at 4 timepoints (fasting, and 1 hour post breakfast, lunch, and dinner) during 6 consecutive days any time before delivery were analyzed. Pregnancy and neonatal outcomes across both groups were compared.

Results: The mean postprandial glucose value following dinner was significantly lesser in the faster aspart group compared to the insulin aspart group (123.61 ± 2.52 mg/dL vs. 125.87 ± 2.98 mg/dL, respectively; p=0.0024). Women in the faster aspart group had significantly lower glycemic variability (fluctuations). Lesser number of hypoglycemic events were noted in the faster aspart group (10 vs. 20; p=0.0595).

Conclusion: Faster aspart was associated with better glycemic control compared to insulin aspart among women with gestational diabetes. Further large-scale studies are needed to validate the outcomes.

Keywords: Faster aspart, insulin aspart, gestational diabetes, glycemic events, glycemic control, glycemic variations.

[1]
American Diabetes Association. 14. Management of diabetes in pregnancy: Standards of medical care in diabetes-2021. Diabetes Care 2021; 44(S1): S200-10.
[http://dx.doi.org/10.2337/dc21-S014] [PMID: 33298425]
[2]
International Diabetes Federation. 2021. Available from: https://diabetesatlas.org/data/en/world/
[3]
Swaminathan G, Swaminathan A, Corsi DJ. Prevalence of gestational diabetes in India by individual socioeconomic, demographic, and clinical factors. JAMA Netw Open 2020; 3(11): e2025074.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.25074] [PMID: 33165611]
[4]
Raja M, Baba T, Hanga A, et al. A study to estimate the prevalence of gestational diabetes mellites in an urban block of Kashmir valley (North India). Int J Med Sci Public Health 2014; 3(2): 191-5.
[http://dx.doi.org/10.5455/ijmsph.2013.211120131]
[5]
Seshiah V, Balaji V, Balaji MS, Sanjeevi CB, Green A. Gestational diabetes mellitus in India. J Assoc Physicians India 2004; 52: 707-11.
[PMID: 15839447]
[6]
Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008; 198(2): 186.e1-7.
[http://dx.doi.org/10.1016/j.ajog.2007.08.005] [PMID: 17905178]
[7]
Figueroa D, Landon MB, Mele L, et al. Relationship between 1-hour glucose challenge test results and perinatal outcomes. Obstet Gynecol 2013; 121(6): 1241-7.
[http://dx.doi.org/10.1097/AOG.0b013e31829277f5] [PMID: 23812458]
[8]
Weisz B, Shrim A, Homko CJ, Schiff E, Epstein GS, Sivan E. One hour versus two hours postprandial glucose measurement in gestational diabetes: a prospective study. J Perinatol 2005; 25(4): 241-4.
[http://dx.doi.org/10.1038/sj.jp.7211243] [PMID: 15605070]
[9]
Jovanovic L. American diabetes association’s fourth international workshop-conference on gestational diabetes mellitus: summary and discussion. Therapeutic interventions. Diabetes Care 1998; 21(S2): B131-7.
[PMID: 9704240]
[10]
Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Diabetes and pregnancy. Int J Gynaecol Obstet 1995; 48(3): 331-9.
[http://dx.doi.org/10.1016/0020-7292(95)90312-7] [PMID: 7781883]
[11]
Gangopadhyay KK, Mukherjee JJ, Sahay RK. Consensus on use of insulins in gestational diabetes. J Assoc Physicians India 2017; 65(3): 16-22.
[PMID: 28832100]
[12]
Kildegaard J, Buckley ST, Nielsen RH, et al. Elucidating the mechanism of absorption of fast-acting insulin aspart: The role of niacinamide. Pharm Res 2019; 36(3): 49.
[http://dx.doi.org/10.1007/s11095-019-2578-7] [PMID: 30746556]
[13]
Cypryk K, Wyrębska-Niewęgłowska A. New faster-acting insulin Fiasp® - do we need a new meal-time insulin? Clinical Diabetology 2019; 7(6): 282-6.
[http://dx.doi.org/10.5603/DK.2018.0031]
[14]
Russell-Jones D, Bode BW, De Block C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: Results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care 2017; 40(7): 943-50.
[http://dx.doi.org/10.2337/dc16-1771] [PMID: 28356319]
[15]
Jebasing FK, Thomas N. Ultrafast acting insulin. RSSDI’s Insulin Monograph (A Complete Guide to Insulin Therapy). (1st ed.). India: JAYPEE 2020; pp. 118-9.
[16]
Bhattacharyya S. SUN-LB117 faster acting insulin aspart in patients with gestational diabetes mellitus - an early experience from India. J Endocr Soc 2020; 4(S1): SUN-LB117.
[17]
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care 2019; 42(8): 1593-603.
[http://dx.doi.org/10.2337/dci19-0028] [PMID: 31177185]
[18]
Basu A, Pieber TR, Hansen AK, et al. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast‐acting insulin aspart compared with insulin aspart. Diabetes Obes Metab 2018; 20(7): 1615-22.
[http://dx.doi.org/10.1111/dom.13270] [PMID: 29493118]
[19]
Senior P, Hramiak I. Fast-acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: A Canadian perspective. Can J Diabetes 2019; 43(7): 515-23.
[http://dx.doi.org/10.1016/j.jcjd.2019.01.004] [PMID: 30872107]
[20]
Evans M, Wilkinson M, Giannpolou A. Fast-acting insulin aspart: The rationale for a new mealtime insulin. Diabetes Ther 2019; 10(5): 1793-800.
[http://dx.doi.org/10.1007/s13300-019-00685-0] [PMID: 31485918]
[21]
Gabbay MAL, Rodacki M, Calliari LE, et al. Time in range: A new parameter to evaluate blood glucose control in patients with diabetes. Diabetol Metab Syndr 2020; 12(1): 22.
[http://dx.doi.org/10.1186/s13098-020-00529-z] [PMID: 32190124]
[22]
Bowering K, Case C, Harvey J, et al. Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: The onset 2 trial. Diabetes Care 2017; 40(7): 951-7.
[http://dx.doi.org/10.2337/dc16-1770] [PMID: 28483786]
[23]
Lane WS, Favaro E, Rathor N, et al. A randomized trial evaluating the efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with insulin degludec with or without metformin, in adults with type 2 diabetes (ONSET 9). Diabetes Care 2020; 43(8): 1710-6.
[http://dx.doi.org/10.2337/dc19-2232] [PMID: 32209647]
[24]
Buse JB, Carlson AL, Komatsu M, et al. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. Diabetes Obes Metab 2018; 20(12): 2885-93.
[http://dx.doi.org/10.1111/dom.13545] [PMID: 30259644]
[25]
Norgaard SK, Mathiesen ER, Nørgaard K. Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy andlactation - a randomised controlled trial. BMJ Open 2021; 11(4): e045650.
[http://dx.doi.org/10.1136/bmjopen-2020-045650] [PMID: 33837106]

Rights & Permissions Print Cite
Article Metrics
47
2
© 2024 Bentham Science Publishers | Privacy Policy